Phase 3 MOJAVE Trial Reports Efficacy of NOV03 for Dry Eye Disease
The second pivotal Phase 3 trial reported NOV03 consistently met primary endpoints for signs and symptoms of DED associated with meibomian gland dysfunction.
Source: hcplive.com
Page 11 - Randomized Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Randomized Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Randomized Phase Today - Breaking & Trending Today
Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
Phase 1b/2 trial in lead KRAS-mutated metastatic colorectal cancer (mCRC) program continues to show our lead candidate onvansertib demonstrates an objective...
Source: prnewswire.com
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Crohn's Disease
The positive CHMP opinion for upadacitinib is based on results from two induction studies and one maintenance study1-4 Crohn's disease is a chronic, systemic...
Source: prnewswire.com
Novaliq Plans to File a Markting Authorisation Application for CyclASol® in the E.U. for the Treatment of Dry Eye Disease in July 2023
L’AFP est une agence d’information globale, assurant une couverture rapide, complète et vérifiée des événements de l’actualité comme des thèmes qui façonnent notre quotidien. Avec un réseau de journalistes sans égal, déployé sur 151 pays, l'AFP est en outre un leader mondial de l’investigation nu...
Source: afp.com
Novaliq Plans to File a Markting Authorisation Application for CyclASol in the E.U. for the Treatment of Dry Eye Disease in July 2023
CHMP determined CyclASol is eligible for a centralised procedure Novaliq has submitted a Letter of intent to file a Marketing Authorisation Application (MAA) in July 2023 Novaliq, a biopharmaceutical
Source: finanznachrichten.de